Janux Therapeutics Inc reports results for the quarter ended in March - Earnings Summary
10/05/2024 22:00
* Janux Therapeutics Inc JANX.OQ reported a quarterly
adjusted
loss of 30 cents per share for the quarter ended in March,
higher than the same quarter last year, when the company
reported EPS of -42 cents. The mean expectation of
eight analysts for the quarter was for a loss of 33 cents per
share. Wall Street expected results to range from -39 cents
to -27 cents per share.
* Revenue fell 38.9% to $1.25 million from a year ago;
analysts
expected $763.38 thousand.
* Janux Therapeutics Inc's reported EPS for the quarter was
a loss
of 30 cents.
* The company reported a quarterly loss of $14.76 million.
* Janux Therapeutics Inc shares had risen by 38.0% this
quarter and gained 384.1% so far this year.
FORECAST CHANGES
* The mean earnings estimate of analysts had risen by
about 18.6%
in the last three months.
* In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company.
RECOMMENDATIONS
* The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 9 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."
* The average consensus recommendation for the biotechnology
&
medical research peer group is also "buy"
Wall Street's median 12-month price target for Janux
Therapeutics Inc is $64.00
This summary was machine generated from LSEG data May 10 at
09:00 p.m. UTC. All figures in US dollars unless otherwise
stated. (For questions concerning the data in this report,
contact Estimates.Support@lseg.com. For any other questions or
feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING ESTIMATE ACTUAL BEAT, MET,
MISSED
Mar. 31 2024 -0.33 -0.30 Beat
Dec. 31 2023 -0.39 -0.25 Beat
Sep. 30 2023 -0.47 -0.25 Beat
Jun. 30 2023 -0.52 -0.42 Beat